ANDEL Trademark

Trademark Overview

On Monday, June 24, 2024, a trademark application was filed for ANDEL with the United States Patent and Trademark Office. The USPTO has given the ANDEL trademark a serial number of 98615714. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, June 24, 2024. This trademark is owned by Goldfine Realty LLC. The ANDEL trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Subscription based pharmaceutical services featuring pharmaceuticals for weight loss, diabetes, alcohol, substance abuse and cardiovascular disease
andel

General Information

Serial Number98615714
Word MarkANDEL
Filing DateMonday, June 24, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateMonday, June 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesSubscription based pharmaceutical services featuring pharmaceuticals for weight loss, diabetes, alcohol, substance abuse and cardiovascular disease
Translation of Words in MarkThe English translation of ANDEL in the mark is SHARE.

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, June 24, 2024
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGoldfine Realty LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressLarchmont, NY 10538

Trademark Events

Event DateEvent Description
Monday, June 24, 2024NEW APPLICATION ENTERED

Related Keywords

andel alcohol diabetes substance abuse disease cardiovascular loss weight pharmaceutical based